文献速递肾小球疾病慢性肾脏病

慢性肾脏病治疗以改善免疫介导性肾小球疾病的结局

CKD therapy to improve outcomes of immune-mediated glomerular diseases.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本文综述免疫介导性肾小球疾病(包括IgA肾病、膜性肾病、狼疮肾炎、ANCA相关血管炎、C3肾小球肾炎、自身免疫性足细胞病等)中慢性肾脏病进展的非免疫机制,讨论非药物干预(限盐、控制体重、避免叠加肾损伤、戒烟、规律运动)和已获批药物干预(肾素-血管紧张素-醛固酮系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂),并探讨在不同临床场景中如何及何时使用这些药物。

要点

  • 管理免疫介导性肾小球疾病须同时控制基础免疫过程与CKD进展的非免疫机制。
  • 非药物干预包括限盐、体重正常化、避免叠加肾损伤、戒烟和规律运动。
  • 已获批药物干预包括RAAS抑制剂和SGLT2抑制剂,多种新药正在临床试验中。

核心结论

  • 免疫介导性肾小球疾病的管理应聚焦于控制基础免疫疾病过程和控制CKD进展的非免疫机制两个核心病理机制。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 非药物干预包括减少盐摄入、体重正常化、避免叠加肾损伤、戒烟和规律运动。
  • 已获批药物干预包括肾素-血管紧张素-醛固酮系统抑制剂和钠-葡萄糖协同转运蛋白2抑制剂。
  • 多种改善CKD治疗的额外药物目前正在临床试验中测试。

临床怎么用

  • 原文讨论了在不同免疫介导性肾脏疾病临床场景中如何及何时使用这些药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of immunoglobulin A nephropathy, membranous nephropathy, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, C3 glomerulonephritis, autoimmune podocytopathies and other immune-mediated glomerular disorders is focused on two major treatment goals, preventing overall mortality and the loss of kidney function. Since minimizing irreversible kidney damage best serves both goals, the management of immune-mediated kidney disorders must focus on the two central pathomechanisms of kidney function decline, i.e., controlling the underlying immune disease process (e.g. with immunotherapies) and controlling the non-immune mechanisms of chronic kidney disease (CKD) progression. Here we review the pathophysiology of these non-immune mechanisms of CKD progression and discuss non-drug and drug interventions to attenuate CKD progression in immune-mediated kidney disorders. Non-pharmacological interventions include reducing salt intake, normalizing body weight, avoiding superimposed kidney injuries, smoking cessation and regular physical activity. Approved drug interventions include inhibitors of the renin-angiotensin-aldosterone system and sodium-glucose cotransporter-2. Numerous additional drugs to improve CKD care are currently being tested in clinical trials. Here we discuss how and when to use these drugs in the different clinical scenarios of immune-mediated kidney diseases.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Anders HJ, Fernandez-Juarez GM, Vaglio A, et al. CKD therapy to improve outcomes of immune-mediated glomerular diseases. Nephrol Dial Transplant. 2023. PMID: 37218706. doi:10.1093/ndt/gfad069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。